GlassScriptPhysician profile
Inhyup Kim
NPI 1659652758
$3,749.51
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,874 · 2020: $1,172 · 2021: $550 · 2022: $154.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $977.84 | 2020 | |
| Medtronic USA, INC. | $795.16 | 2019 | |
| Supernus Pharmaceuticals, INC. | $432.47 | 2019 | |
| Alexion Pharmaceuticals, INC. | $282.97 | 2019-2021 | |
| Mdd US Operations, LLC | $145.85 | 2019 | |
| Avanir Pharmaceuticals, INC. | $140.14 | 2019 | |
| Abbott Laboratories | $139.74 | 2022 | |
| Amgen INC. | $133.53 | 2019 | |
| Medtronic, INC. | $119.44 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $117.73 | 2020 | |
| Sk Life Science, INC. | $116.34 | 2021 | |
| Neurocrine Biosciences, INC. | $96.30 | 2021 | |
| Ucb, INC. | $55.86 | 2019-2020 | |
| Biogen, INC. | $50.99 | 2019-2020 | |
| Emd Serono, INC. | $45.66 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $32.10 | 2019 | |
| Abbvie INC. | $27.57 | 2021-2022 | |
| Lilly USA, LLC | $13.88 | 2019 | |
| Genzyme Corporation | $13.79 | 2019 | |
| Allergan, INC. | $12.15 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inhyup Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.